Login to Your Account

Head Start Gives Merck's Victrelis Little Advantage

By Mari Serebrov

Tuesday, May 17, 2011
News of Friday's FDA approval of Merck & Co. Inc.'s Victrelis as the first new hepatitis C drug in more than a decade is being overshadowed by the impending approval of the next in line, Vertex Pharmaceutical Inc.'s Incivek.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription